Monoclonal antibodies that block immune checkpoints to prevent T cell exhaustion and promote tumor destruction by cytotoxic CD8+ T cells, have been shown to be effective in mCRC patients with dMMR-MSI-H. This evidence concerns the gene CD8A and neoplasm.